Hikma has filed an antitrust suit against Amarin in a federal district court in New Jersey, accusing the originator of anticompetitive conduct to “prevent, delay, and frustrate” generic competition to its Vascepa (icosapent ethyl) purified fish oil brand, following much dialog around generic manufacturers’ ability to source enough of the active pharmaceutical ingredient to mount a material charge.
“Amarin deliberately and meticulously locked up the supply of API icosapent ethyl, in excess of its own needs, in order to reap excessive monopoly profits by thwarting generic competitors from timely bringing affordable and more widely
